• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    36263843.pdf
    Size:
    5.053Mb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Ghione, P.
    Palomba, M. L.
    Ghesquieres, H.
    Bobillo, S.
    Patel, A. R.
    Nahas, M.
    Kanters, S.
    Deighton, K.
    Hatswell, A.
    Ma, L.
    Limbrick-Oldfield, E. H.
    Snider, J. T.
    Wade, S. W.
    Riberio, M. T.
    Radford, John A
    Beygi, S.
    Gribben, J.
    Show allShow less
    Affiliation
    Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Memorial Sloan Kettering Cancer Center, New York, NY
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular lymphoma (FL) patients on 3rd line of treatment (LoT) or higher, for whom existing data are limited. SCHOLAR-5 is a retrospective cohort study using data from adults (≥ 18 years) with grade 1-3a FL, initiating ≥3rd LoT after June 2014 at major lymphoma centers in the United States (US) and Europe. Objective response rate (ORR), complete response (CR), progression free survival (PFS) and overall survival (OS) were analyzed by LoT. Time-to-event outcomes were assessed using Kaplan-Meier methods. Of 128 patients, 87 initiated 3rd LoT, 63 initiated 4th LoT, and 47 initiated 5th LoT. At 1st eligible LoT, 31% progressed within 24-months of 1st LoT anti-CD20 combination therapy, 28% had prior autologous stem-cell transplantation, and 31% were refractory to the previous LoT. The most common regimen in each LoT was chemoimmunotherapy; however, experimental drugs were increasingly used at later LoTs. In the US, anti-CD20 monotherapy was more common at ≥3rd LoT compared to Europe, where stem cell transplants were more common. ORR at 3rd LoT was 68% (CR 44%), but decreased after each LoT to 37% (CR 22%) in ≥5 LoT. Median OS and PFS at 3rd LoT were 68 and 11 months, respectively, and reduced to 43 and 4 months at ≥5 LoT. Treatments were heterogenous at each LoT in both the US and Europe. Few FL patients achieved complete response in later LoT, and duration of response and survival diminished with each subsequent line.
    Citation
    Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, et al. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2022 Oct 20. PubMed PMID: 36263843. Epub 2022/10/21. eng.
    Journal
    Haematologica
    URI
    http://hdl.handle.net/10541/625731
    DOI
    10.3324/haematol.2022.281421
    PubMed ID
    36263843
    Additional Links
    https://dx.doi.org/10.3324/haematol.2022.281421
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.3324/haematol.2022.281421
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.
    • Authors: Kanters S, Ball G, Kahl B, Wiesinger A, Limbrick-Oldfield EH, Sudhindra A, Snider JT, Patel AR
    • Issue date: 2023 Jan 23
    • Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    • Authors: Plosker GL, Figgitt DP
    • Issue date: 2003
    • A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL).
    • Authors: Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Jiménez-Ubieto A, Davis KL, Nagar S, Zhang J, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK
    • Issue date: 2022 Jul
    • Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    • Authors: Ganguly S, Divine CL, Deauna-Limayo D, Bodensteiner DC, Cook JD, Lewis JN, Skikne BS
    • Issue date: 2005 Aug
    • Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    • Authors: Długosz-Danecka M, Hus I, Puła B, Jurczyszyn A, Chojnacki T, Blajer-Olszewska B, Drozd-Sokołowska J, Raźny M, Romejko-Jarosińska J, Taszner M, Jurczak W
    • Issue date: 2019 Jun
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.